Superworth

IDEAYA Biosciences IDYA

Drug Manufacturers - General, Healthcare
$31.64
−1.00%
Market cap
$3.1B
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
13.0×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$234.1M
Net margin
−74.8%
Free cash flow yield
−3.7%

IDEAYA Biosciences trades at 13.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $234.1M over the last twelve months with a −75% net margin.

Charts

Financials

Income statement for IDYA, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$8M−73%$3.9M−3%$0$0$0$7M+79%n/an/a$207.8M$10.9M+55%$6.6M$8.9M
R&D$33.7M+51%$38.8M+57%$42.8M+54%$54.5M+87%$57.2M+70%$140.2M+262%$70.9M+66%$74.2M+36%$83M+45%$86.6M−38%$95.7M+35%$108.7M+46%
SG&A$7.9M+18%$7.1M+23%$8.2M+30%$10.4M+47%$9.7M+24%$11M+55%$13.5M+64%$14.6M+40%$16.4M+68%$18.8M+72%$19.4M+44%$22.5M+54%
−$33.5M−$41.9M+59%−$51M+94%−$64.9M+99%−$66.9M+100%−$144.1M+244%−$84.4M+65%−$88.8M+37%$108.5M−$94.6M−34%−$108.5M+29%−$122.3M+38%
Net income−$27.4M−$34M+40%−$39.6M+67%−$52.8M+89%−$51.8M+89%−$130.3M+284%−$72.2M+82%−$77.5M+47%$119.2M−$83.3M−36%−$98.5M+37%−$112.5M+45%
−$0.46−$0.52+4%−$0.53+8%−$0.68+36%−$0.60+30%−$1.49+187%−$0.82+55%−$0.88+29%$1.33−$0.94−37%−$1.11+35%−$1.22+39%
60M+46%65.2M+36%75.1M+55%78M+39%86.2M+44%87.3M+34%88.4M+18%88.5M+14%89.7M+4%88.6M+1%88.7M+0%92.1M+4%

R&D: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

SG&A: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

Operating income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

Net income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

EPS, diluted: 8 periods, Q1 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY18: share-days: the 6-month average less the second quarter's. 8 periods, Q4 FY18 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest IDEAYA Biosciences' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
IDYAIDEAYA Biosciences$3.1Bn/mn/a13.0×n/m−74.8%
NRIXNurix Therapeutics$2.8B11.1×11.0×4.0×n/m42.0%
OGNOrganon$3.6B18.2×6.0×0.6×−3%3.5%
LQDALiquidia$3.7B30.1×49.4×8.3×n/m30.7%
ARQTArcutis Biotherapeutics$3.9B142×117×8.5×+76%6.1%
PBHPrestige Consumer Healthcare$2.4B13.9×15.3×2.1×−1%15.6%
HRMYHarmony Biosciences$2.2B12.3×13.8×2.3×+24%18.9%
INDVIndivior Pharmaceuticals$4.3B10.2×19.9×3.1×+16%32.8%
ANIPANI Pharmaceuticals$1.6B15.0×57.5×1.7×+31%11.1%
PAHCPhibro Animal Health$1.6B15.9×21.5×1.0×+17%6.6%
LGNDLigand Pharmaceuticals$6.1B32.7×37.6×21.1×+55%67.9%
Peer median$3.2B15.5×20.7×2.7×+21%17.2%

More on IDEAYA Biosciences

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .